Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 891460 | ISIN: AU000000IMU9 | Ticker-Symbol: N/A
1-Jahres-Chart
IMUGENE LIMITED Chart 1 Jahr
5-Tage-Chart
IMUGENE LIMITED 5-Tage-Chart

Aktuelle News zur IMUGENE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiIMUGENE LIMITED: Change of Director's Interest Notice - PH-
FrIMUGENE LIMITED: Notification regarding unquoted securities - IMU3
17.04.IMUGENE LIMITED: Imugene & Kincell Bio Strategic Partnership Investor Webinar-
16.04.CDMO Kincell inks CAR-T supply pact with Imugene, pays $6M for its NC manufacturing site and staff2
16.04.Kincell Bio to Acquire Imugene's NC Mfg. Facility1
16.04.Australia's Imugene drops on plans to sell North Carolina manufacturing facility2
15.04.IMUGENE LIMITED: Imugene and Kincell Bio Announce Strategic Partnership-
15.04.Imugene Limited: Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort121The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma)Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers...
► Artikel lesen
15.04.IMUGENE LIMITED: Notification of cessation of securities - IMU1
15.04.IMUGENE LIMITED: Notification regarding unquoted securities - IMU1
15.04.Imugene expands study for bile tract cancer patients3
14.04.IMUGENE LIMITED: Bile Tract Cancer Study Opens after MAST High Dose Clearance-
09.04.Imugene Limited: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024730Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.Encouraging VAXINIA efficacy, including a complete response (CR) and...
► Artikel lesen
08.04.IMUGENE LIMITED: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting1
04.04.Why Imugene, Liontown, Pointsbet, and Regis Resources shares are storming higher11
04.04.Australia's Imugene rises on China patent for its virus-based cancer therapy1
04.04.Imugene picks up new virotherapy patent in China1
02.04.IMUGENE LIMITED: Oncolytic Virotherapy CF33 Patent Granted in China-
02.04.IMUGENE LIMITED: Cleansing Notice-
02.04.IMUGENE LIMITED: Application for quotation of securities - IMU1
Seite:  Weiter >>
96 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1